- Home
- VERV
as 03-28-2025 4:00pm EST
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 475.0M | IPO Year: | 2021 |
| Target Price: | $25.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.30 - $13.24 | Next Earning Date: | 05-07-2025 |
| Revenue: | $32,332,000 | Revenue Growth: | 174.98% |
| Revenue Growth (this year): | -46.49% | Revenue Growth (next year): | -30.69% |
Latest Verve Therapeutics Inc. News
VERV Breaking Stock News: Dive into VERV Ticker-Specific Updates for Smart Investing
BioPharma Dive
5 days ago
Verve gets FDA green light to expand base editing trial into US
MT Newswires
5 days ago
Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease
GlobeNewswire
5 days ago
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
MT Newswires
25 days ago
RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk
GlobeNewswire
a month ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Verve Therapeutics Full Year 2024 Earnings: Beats Expectations
Zacks
a month ago
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates
Associated Press Finance
a month ago
Verve Therapeutics: Q4 Earnings Snapshot
Compare VERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERV Verve Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.